A number of US pharmaceutical groups have recently made announcements about expanding domestic manufacturing. These include ...

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

Patients with high-risk advanced ovarian cancer obtained a marginal survival benefit with the addition of bevacizumab ...

Pfizer Inc. is cutting at least another $1.2 billion from its spending while the company searches for its next big hit after ...

Announcement pressures pharma stocks on worries profits will be hit if they have to cut prices in US. Read more at ...

Pfizer also said it had measures in place to mitigate the impact of potential tariffs on pharmaceuticals by the Trump administration, including possibly shifting some production to existing ...

He signaled Pfizer could benefit from further tax cuts ... Bourla said the investigation into the national security risks for ...

The company’s CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade ...

Global pharmaceutical shares are slumping Monday after President Donald Trump said he is looking to slash the price of ...

Trump announces US will no longer subsidize foreign healthcare, seeking price cuts on medicines, impacting global ...

Pfizer discontinues danuglipron after liver injury in trial patient Lilly and Novo Nordisk shares rise after Pfizer's decision Pfizer to focus on other obesity research April 14 (Reuters) - Pfizer ...

Shares of pharmaceutical companies fell across the world after US President Donald Trump said he planned to order a cut in US ...